Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Perl AE, et al. Among authors: fathi at. N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688. N Engl J Med. 2019. PMID: 31665578 Clinical Trial.
Lestaurtinib: a multi-targeted FLT3 inhibitor.
Fathi AT, Levis M. Fathi AT, et al. Expert Rev Hematol. 2009 Feb;2(1):17-26. doi: 10.1586/17474086.2.1.17. Expert Rev Hematol. 2009. PMID: 21082990 Review.
FLT3 inhibitors: a story of the old and the new.
Fathi A, Levis M. Fathi A, et al. Curr Opin Hematol. 2011 Mar;18(2):71-6. doi: 10.1097/MOH.0b013e3283439a03. Curr Opin Hematol. 2011. PMID: 21245757 Free PMC article. Review.
A potential therapeutic target for FLT3-ITD AML: PIM1 kinase.
Fathi AT, Arowojolu O, Swinnen I, Sato T, Rajkhowa T, Small D, Marmsater F, Robinson JE, Gross SD, Martinson M, Allen S, Kallan NC, Levis M. Fathi AT, et al. Leuk Res. 2012 Feb;36(2):224-31. doi: 10.1016/j.leukres.2011.07.011. Epub 2011 Jul 29. Leuk Res. 2012. PMID: 21802138 Free PMC article.
FLT3 inhibitor-induced neutrophilic dermatosis.
Fathi AT, Le L, Hasserjian RP, Sadrzadeh H, Levis M, Chen YB. Fathi AT, et al. Blood. 2013 Jul 11;122(2):239-42. doi: 10.1182/blood-2013-01-478172. Epub 2013 May 17. Blood. 2013. PMID: 23687091 Free article.
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.
Chen YB, Li S, Lane AA, Connolly C, Del Rio C, Valles B, Curtis M, Ballen K, Cutler C, Dey BR, El-Jawahri A, Fathi AT, Ho VT, Joyce A, McAfee S, Rudek M, Rajkhowa T, Verselis S, Antin JH, Spitzer TR, Levis M, Soiffer R. Chen YB, et al. Among authors: fathi at. Biol Blood Marrow Transplant. 2014 Dec;20(12):2042-8. doi: 10.1016/j.bbmt.2014.09.007. Epub 2014 Sep 17. Biol Blood Marrow Transplant. 2014. PMID: 25239228 Free PMC article. Clinical Trial.
180 results